Maculo-Anaesthetic Leprosy - Its Diagnosis and Classification

Dharmendra,; Chatterjee, Satya N.

doi:10.5935/0305-7518.19620013

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is difficult to distinguish from Indeterminate leprosy, and some authori ties will call a lesion maculo-anaesthetic whereas others will call it indeterminate , and yet others a tuberculoid macule. Dharmendra (1962), Indian leprologists and others tend to broaden this category to include larger macules with asso ciated neural involvement, which are better considered as part of the Dimorphous type . It would appear preferable to include in maculo anaesthetic only benign patients in which there is never nerve involvement leading to disability.…”

Section: The Spectrum Of Lepro Symentioning

confidence: 99%

The Classification of Leprosy

Pfaltzgraff¹

1967

Leprosy Review

View full text Add to dashboard Cite

Section: The Spectrum Of Lepro Symentioning

confidence: 99%

The Classification of Leprosy

Pfaltzgraff¹

1967

Leprosy Review

View full text Add to dashboard Cite

“…UJ vaccine was the conversion of > 76% of LL patients, 7 1 '/o of BL and 100% of BB patients to a status of lepromin positivity [25]. Retrospective studies of Dharmendara and Chatterjee [30] have shown that lepromin negative contacts of leprosy patients have much higher incidence of leprosy than those who are exposed to infection others. Immunotherapy hastens also the killing of M. leprae [28].…”

Section: Lepromin Conversionmentioning

confidence: 98%

An Immunotherapeutic Vaccine for Multibacillary Leprosy

1999

International Reviews of Immunology

View full text Add to dashboard Cite

On January 30, 1998, a vaccine for leprosy based on Mycobacterium w (the code word under which this species hitherto unspecified was investigated) was launched for public use for therapeutic purposes. The vaccine has completed phase III immunotherapeutic trials as an adjunct to chemotherapy in urban and rural leprosy control centres and has received the authorization from the Drugs Controller of India for industrial manufacture. It will be made available by M/s Cadila Pharmaceuticals, Ahmedabad. As an adjunct to chemotherapy, the vaccine expediates bacterial clearance and accelerates clinical regression of lesions. It shortens significantly the period for release from treatment (RFT) of patients. It is effective in inducing a fall of bacterial index (BI) in multibacillary patients who are either nonresponders or slow responders to the standard multidrug therapy and who have persistent BI over long periods. An additional benefit of immunization with this vaccine is the conversion of>60% of LL, 71% of BL and 100% of BB patients from lepromin negativity to lepromin positivity status. A significant number of vaccinated patients showed histopathological upgrading and eventually attainment of a state of nonspecific infiltration without dermal granulomas. The vaccine was well tolerated and the incidence of Type 2 reactions and their severity was less in combined immuno cum chemotherapy group than in the group receiving only chemotherapy. This review describes the nature of the vaccine and the way it was developed.

show abstract

“…Macular and hypopigmented leprosy lesions are known to occur anywhere on the body, but are often found on visible sites such as the face and lateral or dorsal aspects of extremities. 23 In a cross sectional study from central India, of the 160 leprosy patients examined, 64 (40%) presented with hypopigmented facial cutaneous lesions. 24 Facial patches of leprosy can be both pale, flat, and macular type or red raised patches in reaction.…”

Section: Pe R Si Sten T Fac Ia L Pat C He S In Leprosymentioning

confidence: 99%

Cosmetic camouflage of visible skin lesions enhances life quality indices in leprosy as in vitiligo patients: an effective stigma reduction strategy

Rao¹,

Vellala²,

Potharaju³

et al. 2020

LEPROSY

View full text Add to dashboard Cite

The use of cosmetic camouflage for blemishes on skin of affected people is known to improve their Dermatology Life Quality Index (DLQI). Although the use and benefits of cosmetic camouflage is known and reported in vitiligo, its value in leprosy, where visible skin lesions are a reason for stigma and discrimination, is yet to be explored. A key resolution of the WHO Global Leprosy Strategy 2016-2020 is to stop discrimination and promote inclusion of persons affected by leprosy into society. Improving the DLQI of leprosy patients with the use of cosmetic camouflage is an effort in that direction.Objectives: We undertook this study to examine the change brought about by cosmetic camouflage in the DLQI of leprosy patients with visible skin lesions and, to compare the results with its use in vitiligo, as both are disorders associated with pigment dilution in the skin. Methods: The DLQI score was calculated for 9 consenting leprosy and 14 vitiligo patients at the time of enrolment. All patients were taught the simple technique of cosmetic camouflage of their skin patches on exposed parts of the body, such as face and arms/forearms. The DLQI scoring was calculated again after one month of use of cosmetic camouflage and compared with the baseline value.Results: The mean DLQI improved significantly (p < 0.0001) after the use of cosmetic camouflage in both vitiligo and leprosy groups, indicating the efficacy of camouflage in improving the quality of life. In addition, it was observed that the mean improvement in DLQI was higher in the leprosy group (14.67 ± 3.87) than in the vitiligo group (8.64 ± 2.96), the difference being statistically significant (p < 0.05), suggesting that camouflage has a very high impact on the quality of life in leprosy. Conclusions: Leprosy-related stigma and discrimination are pervasive in almost all cultures of the world. Such stigma affects many aspects of social participation. The WHO global strategy document 2016-2020 advocates inclusion of at least one stigma reduction strategy in all leprosy programme plans. Use of cosmetic camouflage for

show abstract

Maculo-Anaesthetic Leprosy - Its Diagnosis and Classification

Abstract: • The present paper refers only to the "simple" nat benign lesions of leprosy and comments on the subject have theref ore been limited mainly to cover this type of lesion.

Cited by 4 publications

References 0 publications

The Classification of Leprosy

The Classification of Leprosy

An Immunotherapeutic Vaccine for Multibacillary Leprosy

Cosmetic camouflage of visible skin lesions enhances life quality indices in leprosy as in vitiligo patients: an effective stigma reduction strategy

Contact Info

Product

Resources

About